Nancy Kerrigan

After the football and the turkey, tune in Kaleidoscope on Thanksgiving.  C3 is part of the show!

Featuring cancer survivors Dorothy Hamill, Scott Hamilton, and Olivia Newton-John, Kaleidoscope focuses on women and cancer, raising awareness of how cancer affects women and providing strength to triumph over it.

Taped before an audience almost entirely of cancer survivors, Kaleidoscope will air at 4 p.m. EST, Thursday, November 26, Thanksgiving Day on FOX.

Watch for the more than 200 C3 cancer survivors and their families who were at the taping in the Verizon Center. Read the rest of this entry »

There are a number of provisions in both the House and Senate health care reform bills that will affect colorectal cancer patients.  Click here to see a chart outlining and comparing these provisions.

Read the rest of this entry »

Dr. Val Jones used slides and limericks to warn that looking for health information online can be both good and bad.

Addressing the e-Patients Connections 2009 conference in Philadelphia in October, she compared two patients whose online information experiences led to very different results — one happy, one tragic. Read the rest of this entry »

Recent publications have questioned the safety and adequacy of cancer screening procedures particular mammograms, but today I am reviewing the risks of colonoscopies.

There is no doubt that colonoscopies can prevent colon cancer almost 100%. Read the rest of this entry »

By Nancy Roach, the Founder of C3 and Chair of its Board of Directors

On November 4, the National Cancer Institute (NCI) held the 9th meeting of the Clinical Trials and Translational Research Advisory Committee (CTAC). CTAC advises NCI on the implementation of the 2006 recommendations from Clinical Trials Working Group and the 2008 recommendations for the Translational Research Working Group. There’s more information about NCI’s initiatives here.

I am one of two advocates who serve on CTAC, and as an ex-systems analyst, I’m always looking for ways to make government more efficient and accountable.  At the November 4 meeting, recommendations were presented to increase the efficiency of the clinical trial development process – from the time that a researcher presents a concept to NCI to the time that the trial is actually activated.  Under the leadership of Dr. James Doroshow, NCI and its partners are taking aggressive steps to de-bureaucratize publicly-funded cancer research, which will ultimately benefit patients by putting resources into research instead of process.

Following is a very brief overview of the background and the recommendations, with links to additional documentation. And believe it or not, zombies did come up in the discussion!

Read the rest of this entry »